{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:59:08Z","timestamp":1781632748937,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Hepatocellular carcinoma (HCC) is one of the most frequent causes of cancer-related death worldwide. Mirroring the complexity of human HCC with its underlying liver disease requires multilocular orthotopic tumor models in mice, where objective tumor quantification in vivo is challenging, especially longitudinally. We investigated magnetic resonance imaging (MRI) to noninvasively quantify orthotopic HCC in an immunotherapy setting. Orthotopic HCCs were induced in diethylnitrosamine (DEN)-injected mice with either CCl\n                    <jats:sub>4<\/jats:sub>\n                    -induced hepatic fibrosis or dietary metabolic dysfunction-associated steatotic liver disease (MASLD) to mirror the most frequent etiologies. Growth kinetics over the course of immune checkpoint inhibitor treatment with anti-Programmed Death Ligand 1 (\u03b1PD-L1) were modeled by measuring the overall tumor burden (OTB) using MRI and compared to untreated animals. Tumor parameters, such as tumor volume, liver weights at sacrifice and largest tumor diameter were analyzed. We demonstrate that MRI is a reliable imaging tool for both pretreatment tumor confirmation as well as the longitudinal quantification of overall tumor burden under investigational treatment. While measuring only the largest tumor diameter yielded significant differences between \u03b1PD-L1-treated animals and untreated controls in the long-term setting, these trends in tumor response were not confirmed by MRI-based OTB measurement. In MASLD-HCC, tumors did not respond to PD-L1 blockade, thus confirming the OTB data and reflecting the immunotherapy resistance observed in the human setting and highlighting the translational relevance of the model. Orthotopic fibrosis-HCC and MASLD-HCC mouse models can be enhanced through the longitudinal use of MRI while reducing endpoints and animal numbers. The DEN-CCl\n                    <jats:sub>4<\/jats:sub>\n                    and DEN-Western Diet models mirror the \u03b1PD-L1 response from the human setting and require OTB measurement, because largest diameters may underestimate the total tumor mass in orthotopic HCC.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-38125-2","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T09:23:53Z","timestamp":1770283433000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quantification of overall tumor burden using longitudinal magnetic resonance imaging improves response assessment in orthotopic murine hepatocellular carcinoma models"],"prefix":"10.1038","volume":"16","author":[{"given":"Isabella","family":"Lurje","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebke","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Hilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay-Mohan","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Reers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Schlutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kuzminskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaroslava","family":"Shevchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leke","family":"Wiering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Eichhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Beindorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Tacke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Hammerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"issue":"1","key":"38125_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Primers. 7 (1), 6 (2021).","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"6","key":"38125_CR2","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","volume":"77","author":"H Rumgay","year":"2022","unstructured":"Rumgay, H. et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J. Hepatol. 77 (6), 1598\u20131606 (2022).","journal-title":"J. Hepatol."},{"key":"38125_CR3","doi-asserted-by":"publisher","first-page":"101191","DOI":"10.1016\/j.mam.2023.101191","volume":"92","author":"I Lurje","year":"2023","unstructured":"Lurje, I. et al. Mechanisms of organ fibrosis: emerging concepts and implications for novel treatment strategies. Mol. Aspects Med. 92, 101191 (2023).","journal-title":"Mol. Aspects Med."},{"issue":"6","key":"38125_CR4","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/hep4.1510","volume":"4","author":"JM Paik","year":"2020","unstructured":"Paik, J. M. et al. Nonalcoholic fatty liver disease and alcoholic liver disease are major drivers of liver mortality in the united States. Hepatol. Commun. 4 (6), 890\u2013903 (2020).","journal-title":"Hepatol. Commun."},{"issue":"2","key":"38125_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","volume":"82","author":"B Sangro","year":"2025","unstructured":"Sangro, B. et al. EASL clinical practice guidelines on the management of hepatocellular carcinoma. J. Hepatol. 82 (2), 315\u2013374 (2025).","journal-title":"J. Hepatol."},{"issue":"6","key":"38125_CR6","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/s41591-021-01344-3","volume":"27","author":"A Deczkowska","year":"2021","unstructured":"Deczkowska, A. et al. XCR1(+) type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis. Nat. Med. 27 (6), 1043\u20131054 (2021).","journal-title":"Nat. Med."},{"key":"38125_CR7","doi-asserted-by":"crossref","unstructured":"Uluk, D. et al. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Impacts Long-Term Outcomes after Curative-Intent Surgery for Hepatocellular Carcinoma (Aliment Pharmacol Ther, 2025).","DOI":"10.1111\/apt.70002"},{"issue":"20","key":"38125_CR8","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl. J. Med. 382 (20), 1894\u20131905 (2020).","journal-title":"N Engl. J. Med."},{"issue":"2","key":"38125_CR9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1055\/a-2334-8311","volume":"44","author":"W Werner","year":"2024","unstructured":"Werner, W. et al. Overcoming resistance to immune checkpoint Blockade in liver cancer with combination therapy: stronger together? Semin Liver Dis. 44 (2), 159\u2013179 (2024).","journal-title":"Semin Liver Dis."},{"issue":"7854","key":"38125_CR10","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","volume":"592","author":"D Pfister","year":"2021","unstructured":"Pfister, D. et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 592 (7854), 450\u2013456 (2021).","journal-title":"Nature"},{"key":"38125_CR11","doi-asserted-by":"publisher","first-page":"650486","DOI":"10.3389\/fimmu.2021.650486","volume":"12","author":"I Lurje","year":"2021","unstructured":"Lurje, I. et al. In situ vaccination as a strategy to modulate the immune microenvironment of hepatocellular carcinoma. Front. Immunol. 12, 650486 (2021).","journal-title":"Front. Immunol."},{"issue":"7","key":"38125_CR12","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1158\/1541-7786.MCR-18-1045","volume":"17","author":"J Friemel","year":"2019","unstructured":"Friemel, J. et al. Characterization of HCC mouse models: towards an Etiology-Oriented subtyping approach. Mol. Cancer Res. 17 (7), 1493\u20131502 (2019).","journal-title":"Mol. Cancer Res."},{"issue":"1 Suppl","key":"38125_CR13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/0023677215570086","volume":"49","author":"R Tolba","year":"2015","unstructured":"Tolba, R. et al. Diethylnitrosamine (DEN)-induced carcinogenic liver injury in mice. Lab. Anim. 49 (1 Suppl), 59\u201369 (2015).","journal-title":"Lab. Anim."},{"key":"38125_CR14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/1476-4598-9-219","volume":"9","author":"F Heindryckx","year":"2010","unstructured":"Heindryckx, F. et al. Kinetics of angiogenic changes in a new mouse model for hepatocellular carcinoma. Mol. Cancer. 9, 219 (2010).","journal-title":"Mol. Cancer"},{"key":"38125_CR15","doi-asserted-by":"publisher","first-page":"111376","DOI":"10.1016\/j.intimp.2023.111376","volume":"127","author":"X Luo","year":"2024","unstructured":"Luo, X. et al. SRSF10 facilitates HCC growth and metastasis by suppressing CD8\u2009+\u2009T cell infiltration and targeting SRSF10 enhances anti-PD-L1 therapy. Int. Immunopharmacol. 127, 111376 (2024).","journal-title":"Int. Immunopharmacol."},{"issue":"12","key":"38125_CR16","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1111\/bph.15427","volume":"178","author":"A Kannt","year":"2021","unstructured":"Kannt, A. et al. Activation of thyroid hormone receptor-\u03b2 improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis. Br. J. Pharmacol. 178 (12), 2412\u20132423 (2021).","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"38125_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.jhep.2014.10.024","volume":"62","author":"ME Healy","year":"2015","unstructured":"Healy, M. E. et al. Dietary effects on liver tumor burden in mice treated with the hepatocellular carcinogen diethylnitrosamine. J. Hepatol. 62 (3), 599\u2013606 (2015).","journal-title":"J. Hepatol."},{"key":"#cr-split#-38125_CR18.1","unstructured":"Dowland, S. Haematoxylin and Eosin (H&E) staining of paraffin sections. [cited 2025 2025\/06\/01]"},{"key":"#cr-split#-38125_CR18.2","doi-asserted-by":"crossref","unstructured":"(2005). Available from: https:\/\/dx.doi.org\/10.17504\/protocols.io.n92ld5b3xv5b\/v1.","DOI":"10.17504\/protocols.io.n92ld5b3xv5b\/v1"},{"issue":"7","key":"38125_CR19","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods. 9 (7), 676\u2013682 (2012).","journal-title":"Nat. Methods"},{"issue":"19","key":"38125_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21197378","volume":"21","author":"I. Lurje","year":"2020","unstructured":"Lurje, I., Hammerich, L. & Tacke, F. Dendritic cell and T cell crosstalk in liver fibrogenesis and hepatocarcinogenesis: implications for prevention and therapy of liver cancer. Int. J. Mol. Sci. 21 (19), 1 (2020).","journal-title":"Int. J. Mol. Sci."},{"issue":"7854","key":"38125_CR21","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41586-021-03233-8","volume":"592","author":"M Dudek","year":"2021","unstructured":"Dudek, M. et al. Auto-aggressive CXCR6(+) CD8 T cells cause liver immune pathology in NASH. Nature 592 (7854), 444\u2013449 (2021).","journal-title":"Nature"},{"issue":"1","key":"38125_CR22","doi-asserted-by":"publisher","first-page":"8013","DOI":"10.1038\/s41598-024-58587-6","volume":"14","author":"Q Zhang","year":"2024","unstructured":"Zhang, Q. et al. Proteomic analysis of DEN and CCl(4)-induced hepatocellular carcinoma mouse model. Sci. Rep. 14 (1), 8013 (2024).","journal-title":"Sci. Rep."},{"issue":"8","key":"38125_CR23","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/s42255-022-00616-7","volume":"4","author":"F Liu","year":"2022","unstructured":"Liu, F. et al. Long non-coding RNA SNHG6 couples cholesterol sensing with mTORC1 activation in hepatocellular carcinoma. Nat. Metab. 4 (8), 1022\u20131040 (2022).","journal-title":"Nat. Metab."},{"issue":"1","key":"38125_CR24","doi-asserted-by":"publisher","first-page":"5945","DOI":"10.1038\/s41467-022-33493-5","volume":"13","author":"C Ge","year":"2022","unstructured":"Ge, C. et al. Hepatocyte phosphatase DUSP22 mitigates NASH-HCC progression by targeting FAK. Nat. Commun. 13 (1), 5945 (2022).","journal-title":"Nat. Commun."},{"issue":"8080","key":"38125_CR25","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41586-025-09297-0","volume":"645","author":"J Gautam","year":"2025","unstructured":"Gautam, J. et al. ACLY Inhibition promotes tumour immunity and suppresses liver cancer. Nature 645 (8080), 507\u2013517 (2025).","journal-title":"Nature"},{"issue":"3","key":"38125_CR26","first-page":"427","volume":"4","author":"X Li","year":"2005","unstructured":"Li, X. et al. Magnetic resonance imaging of hepatocellular carcinoma induced by diethylnitrosamine in Sprague-Dawley rats. Hepatobiliary Pancreat. Dis. Int. 4 (3), 427\u2013432 (2005).","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"38125_CR27","doi-asserted-by":"crossref","unstructured":"Byrne, F. L. et al. Serial MRI imaging reveals minimal impact of ketogenic diet on established liver tumor growth. Cancers (Basel), 10(9). (2018).","DOI":"10.3390\/cancers10090312"},{"key":"38125_CR28","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/1476-4598-9-94","volume":"9","author":"J Freimuth","year":"2010","unstructured":"Freimuth, J. et al. Application of magnetic resonance imaging in Transgenic and chemical mouse models of hepatocellular carcinoma. Mol. Cancer. 9, 94 (2010).","journal-title":"Mol. Cancer"},{"key":"38125_CR29","doi-asserted-by":"publisher","first-page":"1177421","DOI":"10.3389\/fphar.2023.1177421","volume":"14","author":"M Obrecht","year":"2023","unstructured":"Obrecht, M. et al. Magnetic resonance imaging and ultrasound elastography in the context of preclinical Pharmacological research: significance for the 3R principles. Front. Pharmacol. 14, 1177421 (2023).","journal-title":"Front. Pharmacol."},{"issue":"2","key":"38125_CR30","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3164\/jcbn.2008022","volume":"42","author":"S Akagiri","year":"2008","unstructured":"Akagiri, S. et al. A mouse model of metabolic Syndrome; increase in visceral adipose tissue precedes the development of fatty liver and insulin resistance in High-Fat Diet-Fed male KK\/Ta mice. J. Clin. Biochem. Nutr. 42 (2), 150\u2013157 (2008).","journal-title":"J. Clin. Biochem. Nutr."},{"issue":"5","key":"38125_CR31","first-page":"708","volume":"5","author":"Y Liu","year":"2015","unstructured":"Liu, Y. et al. Mammalian models of chemically induced primary malignancies exploitable for imaging-based preclinical theragnostic research. Quant. Imaging Med. Surg. 5 (5), 708\u2013729 (2015).","journal-title":"Quant. Imaging Med. Surg."},{"issue":"8","key":"38125_CR32","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1038\/s44319-025-00429-1","volume":"26","author":"K Riesner","year":"2025","unstructured":"Riesner, K. et al. What must not be named: Facts, emotions and coping strategies to enhance animal welfare in research. EMBO Rep. 26 (8), 1929\u20131934 (2025).","journal-title":"EMBO Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38125-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38125-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38125-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:35:45Z","timestamp":1781631345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38125-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["38125"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-38125-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"12 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5247"}}